1. Home
  2. THRD vs DLNG Comparison

THRD vs DLNG Comparison

Compare THRD & DLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • THRD
  • DLNG
  • Stock Information
  • Founded
  • THRD 2019
  • DLNG 2013
  • Country
  • THRD United States
  • DLNG Greece
  • Employees
  • THRD N/A
  • DLNG N/A
  • Industry
  • THRD Biotechnology: Pharmaceutical Preparations
  • DLNG Marine Transportation
  • Sector
  • THRD Health Care
  • DLNG Consumer Discretionary
  • Exchange
  • THRD Nasdaq
  • DLNG Nasdaq
  • Market Cap
  • THRD 157.7M
  • DLNG 143.7M
  • IPO Year
  • THRD 2022
  • DLNG 2013
  • Fundamental
  • Price
  • THRD $3.55
  • DLNG $3.82
  • Analyst Decision
  • THRD Hold
  • DLNG
  • Analyst Count
  • THRD 3
  • DLNG 0
  • Target Price
  • THRD $5.00
  • DLNG N/A
  • AVG Volume (30 Days)
  • THRD 343.0K
  • DLNG 43.5K
  • Earning Date
  • THRD 05-14-2025
  • DLNG 03-06-2025
  • Dividend Yield
  • THRD N/A
  • DLNG 2.59%
  • EPS Growth
  • THRD N/A
  • DLNG 112.55
  • EPS
  • THRD N/A
  • DLNG 1.40
  • Revenue
  • THRD N/A
  • DLNG $156,403,000.00
  • Revenue This Year
  • THRD N/A
  • DLNG N/A
  • Revenue Next Year
  • THRD N/A
  • DLNG $0.37
  • P/E Ratio
  • THRD N/A
  • DLNG $2.74
  • Revenue Growth
  • THRD N/A
  • DLNG N/A
  • 52 Week Low
  • THRD $3.18
  • DLNG $2.84
  • 52 Week High
  • THRD $16.94
  • DLNG $5.65
  • Technical
  • Relative Strength Index (RSI)
  • THRD 42.90
  • DLNG 40.71
  • Support Level
  • THRD $3.34
  • DLNG $3.74
  • Resistance Level
  • THRD $3.68
  • DLNG $3.99
  • Average True Range (ATR)
  • THRD 0.14
  • DLNG 0.12
  • MACD
  • THRD 0.07
  • DLNG 0.02
  • Stochastic Oscillator
  • THRD 62.86
  • DLNG 25.89

About THRD Third Harmonic Bio Inc.

Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.

About DLNG Dynagas LNG Partners LP Common Units

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

Share on Social Networks: